Q-omics provides the consensus-scored GUCA1A profile across patient tissues and cancer cell-line models. GUCA1A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GUCA1A is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, GUCA1A RNA expression shows 10,947 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, LUAD, and ESCA as cancer lineages where GUCA1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUCA1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUCA1A survival associations across molecular data types. GUCA1A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUCA1A RNA expression–survival associations across cancer types. High GUCA1A expression shows unfavorable associations in KIRC, ACC, MESO, CESC and GBM, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GUCA1A RNA expression.
This table summarizes GUCA1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GUCA1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUCA1A shows lower tumor expression in KICH and higher tumor expression in LUAD, HNSC, LUSC, BRCA and BLCA. The LUAD box plot shows higher GUCA1A RNA expression in tumor versus normal tissue (log2 FC = +0.726, t-test p < 0.001).
This table shows molecular features associated with GUCA1A in patient tissues and cancer cell lines. In patient samples, GUCA1A shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, GUCA1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
